PubMed,
Год журнала:
2023,
Номер
3(2), С. e121 - e121
Опубликована: Авг. 1, 2023
N-acetylcysteine
has
antioxidant
and
anti-inflammatory
activities
that
could
potentially
improve
the
clinical
outcomes
of
coronavirus
disease
2019
(COVID-19)
patients.
inhibits
NLRP3
(NOD-,
LRR-
pyrin
domain-containing
protein
3)
inflammasome
results
in
control
oxidative
stress
cytokine
release
COVID-19
The
aim
this
study
was
to
assess
effect
reducing
neutrophil-lymphocyte
ratio
(NLR)
A
randomized
controlled
trial
conducted
among
severe
moderate
treatment
group
received
oral
1200
mg
daily
(three
times
a
day)
standard
care
for
COVID-19,
while
placebo.
NLR
determined
on
first
day
admission
after
seventh
treatment.
paired
Student
t-test
used
compare
before
independent
between
groups.
total
40
were
enrolled,
20
people
each
group,
with
mean
age
44.68±13.24
years
old.
9.44
8.84
group.
After
day,
4.27
11.54
respectively.
changes
(the
pre-treatment
compared
post-treatment)
reduced
4.05
increased
3.34,
significantly
decreased
(
Heliyon,
Год журнала:
2024,
Номер
10(3), С. e25179 - e25179
Опубликована: Янв. 26, 2024
The
association
between
N-acetylcysteine
(NAC)
and
COVID-19
remains
undetermined;
therefore,
this
meta-analysis
assessed
the
clinical
efficacy
of
NAC
in
treatment
patients
with
COVID-19.
PubMed,
Год журнала:
2023,
Номер
3(2), С. e121 - e121
Опубликована: Авг. 1, 2023
N-acetylcysteine
has
antioxidant
and
anti-inflammatory
activities
that
could
potentially
improve
the
clinical
outcomes
of
coronavirus
disease
2019
(COVID-19)
patients.
inhibits
NLRP3
(NOD-,
LRR-
pyrin
domain-containing
protein
3)
inflammasome
results
in
control
oxidative
stress
cytokine
release
COVID-19
The
aim
this
study
was
to
assess
effect
reducing
neutrophil-lymphocyte
ratio
(NLR)
A
randomized
controlled
trial
conducted
among
severe
moderate
treatment
group
received
oral
1200
mg
daily
(three
times
a
day)
standard
care
for
COVID-19,
while
placebo.
NLR
determined
on
first
day
admission
after
seventh
treatment.
paired
Student
t-test
used
compare
before
independent
between
groups.
total
40
were
enrolled,
20
people
each
group,
with
mean
age
44.68±13.24
years
old.
9.44
8.84
group.
After
day,
4.27
11.54
respectively.
changes
(the
pre-treatment
compared
post-treatment)
reduced
4.05
increased
3.34,
significantly
decreased
(
